NovaBone Products has introduced a syringe delivery system specifically designed for the foot and ankle market to deliver its bioactive glass putty device.
ALACHUA, Fla., Sept. 18, 2023 /PRNewswire-PRWeb/ — NovaBone Products, a leader in synthetic biologics, has commercially launched a new syringe for targeted delivery of its 45S5 bioactive glass putty device for the foot and ankle market. The syringe is available in 2.5cc and 5cc formulations.
“We are excited to provide our foot and ankle surgeons with a specific solution to deliver our best-in-class synthetic putty to their patients. This is NovaBone’s first product specifically designed for the foot and ankle market. Along with our NovaForm Wound Matrix clearance earlier this year, this shows our commitment to diversifying our portfolio, leveraging our Bioactive Glass manufacturing expertise, and providing surgeons in multiple specialties with solutions best suited for their patients,” said Sean Finnerty, Executive Vice President of Sales and Marketing at NovaBone.
NovaBone’s Putty, cleared by the FDA in 2006, is an effective bone graft substitute that closely mimics the mineral composition of natural bone. It provides an ideal environment for new bone formation, facilitating the integration of graft material and host tissue.
The foot and ankle syringe is commercially available in the US Market. Dr. Charles E. Cook of Dallas, Texas, was the first foot and ankle surgeon to use the new product designed for medical use of bioactive glass.
“I had the opportunity to use the new 2.5cc syringe delivery system in the OR today. The putty met all my needs and expectations. The putty flowed nicely into the osseous defect, and the putty’s viscosity provided a nice tapenade effect, providing hemostasis. I have been using the larger volume delivery system of NovaBone putty in my practice with great success, and these smaller delivery systems are a much-needed addition for diverse applications,” said Dr. Cook.
For more information on the new bioactive glass syringe, contact us today by visiting our website, novabone.com.
About NovaBone
NovaBone, a Halma company, has been privately held and based in Florida since 2002. It developed the first bioactive glass for bone healing offered to the orthopedic community and has been at the forefront of bioactive glass bone graft devices. NovaBone has developed numerous formulations and delivery systems of its patented, bioactive glass technology platform that accelerates bone growth. Their bone graft substitute has been used for over a decade in the repair of osseous defects throughout the skeletal system, with over a million clinical applications and unparalleled success, demonstrating the safety and efficacy of NovaBone’s technology.
Media Contact
Sean P. Finnerty, NovaBone Products, 1 908 432 3353, [email protected], www.novabone.com
SOURCE NovaBone Products
